Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.60
+0.72 (5.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Inhibrx Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 1.57 | 1.63 | 1.32 |
| Revenue Growth (YoY) | 19.24% | 24.26% | - |
| Cost of Revenue | 190.96 | 130.13 | 101.6 |
| Gross Profit | -189.39 | -128.5 | -100.29 |
| Selling, General & Admin | 113.94 | 24.25 | 15.04 |
| Operating Expenses | 113.94 | 24.25 | 15.04 |
| Operating Income | -303.34 | -152.75 | -115.32 |
| Earnings From Equity Investments | -1.63 | -1.63 | - |
| Other Non Operating Income (Expenses) | -0.14 | -0.58 | 0 |
| Pretax Income | 1,728 | -154.96 | -115.32 |
| Income Tax Expense | -0 | 0 | 0 |
| Net Income | 1,728 | -154.96 | -115.33 |
| Net Income to Common | 1,728 | -154.96 | -115.33 |
| Free Cash Flow | -149.23 | -133.6 | -91.5 |
| Operating Margin | -19345.34% | -9348.04% | -8769.81% |
| Profit Margin | 110218.75% | -9483.72% | -8769.96% |
| Free Cash Flow Margin | -9517.28% | -8176.25% | -6957.95% |
| EBITDA | -301.44 | -151.56 | -114.1 |
| D&A For EBITDA | 1.89 | 1.19 | 1.23 |
| EBIT | -303.34 | -152.75 | -115.32 |
| Revenue as Reported | 1.57 | 1.63 | 1.32 |
Source: S&P Capital IQ. Standard template.
Financial Sources.